![]() ![]() The discovery of new molecular alterations and development of respective targeted treatments represents a major improvement over conventional chemotherapy when applied to appropriately selected patient populations. The 5-year overall survival (OS) of advanced NSCLC (aNSCLC) is about 26% in stage IIIB and 10%/1% in stage IVA/IVB patients. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all diagnosed lung cancer cases. In women, according to latest mortality projections, lung cancer age-standardized mortality rate will surpass breast cancer mortality rate before 2030 in many countries. Lung cancer is the leading cause of cancer death in men and the third most frequent cause of cancer death in women worldwide, with 2♱ million new cases and 1♷ million deaths estimated for 2018. Still, the majority of German aNSCLC patients do not receive a mutation test. Conclusionsĭespite the introduction of new treatments, the real-world survival prognosis for aNSCLC patients remains poor if measured based on an unselected real-world population of patients. On the other hand, female gender and treatment with therapies other than chemotherapy were associated with a lower risk of early death. In a multivariable Cox regression analysis, higher age, a stage IV disease, a higher number of chronic drugs in the pre-index period and no systemic therapy increased the risk of early death since first aNSCLC diagnosis. Median OS since incident diagnosis was 351 days in all and 571 days in mutation-positive patients. Most often prescribed treatments were pemetrexed monotherapy as 1 L (21♲3% for all and 11♱1% for mutation-positive patients) and erlotinib monotherapy as 2 L (25♸3%/38♵4%). The mutation test rate within this population was 26♳1% ( n = 458), 26♶% of these patients ( n = 122) received a targeted treatment and were assumed to have a positive EGFR/ALK/ROS-1 test result. Overall, 1741 aNSCLC patients were observed (mean age: 66♹7 years, female: 29♸7%). Factors associated with OS were analyzed in multivariable Cox regression analysis. ![]() Further, prescribed treatments and OS since first (incident) aNSCLC diagnosis and start of respective treatment lines were described both for all patients and presumed EGFR/ALK/ROS-1-positive patients. ![]() Inpatient and outpatient mutation test procedures after aNSCLC diagnosis were observed. Identification of eligible patients took place between –, to allow for at least 1-year pre-index and follow-up periods. This was a retrospective German claims data analysis of incident aNSCLC patients. Call our National Cancer Information Center at 1-80 and speak with one of our trained specialists.The objective of this study was to describe the real-world treatment and overall survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer (aNSCLC), and to explore factors associated with the real-world mortality risk. The American Cancer Society also has programs and services – including rides to treatment, lodging, and more – to help you get through treatment. These might include nursing or social work services, financial aid, nutritional advice, rehab, or spiritual help. Whether you are thinking about treatment, getting treatment, or not being treated at all, you can still get supportive care to help with pain or other symptoms. Communicating with your cancer care team is important so you understand your diagnosis, what treatment is recommended, and ways to maintain or improve your quality of life.ĭifferent types of programs and support services may be helpful, and can be an important part of your care. People with cancer need support and information, no matter what stage of illness they may be in. Knowing all of your options and finding the resources you need will help you make informed decisions about your care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |